ctDNA Analyses Predict Early Progression with First-Line Lorlatinib in ALK+ NSCLC

This study from the CROWN trial links circulating tumor DNA (ctDNA) analyses to early progression outcomes in ALK-positive non-small cell lung cancer (NSCLC) treated with first-line lorlatinib. The findings specifically associate TP53 status and tumor fraction measured by ctDNA with patient outcomes, highlighting potential biomarkers for treatment response.

Originally published by gnews